22nd February 2022
VENTURE LIFE GROUP PLC
("Venture Life" "VLG" or the "Group")
Grant of Options
Venture Life (AIM: VLG), a leader in developing, manufacturing and commercialising products for the self-care market, has, on the recommendation of the Company's Remuneration Committee, issued options over 300,000 ordinary shares of 0.3 pence each in the Company to Daniel Wells, Chief Financial Officer. Mr Wells has been awarded 300,000 unapproved share options under the Company's Share Option Plan, with an exercise price of 43.0 pence per share, being the closing mid-market price on 21st February 2022. The vesting of these options is subject to continuing employment and the satisfaction of performance conditions based on profitability and TSR targets. The options become exercisable on 31st March 2025.
As a results of the issue of these share options, Daniel Wells holds options over a total of 445,349 ordinary shares in the Company.
For further information, please contact:
| Venture Life Group PLC | +44 (0) 1344 578004 | ||
| Jerry Randall, Chief Executive Officer Daniel Wells, Chief Financial Officer |
| ||
|
Cenkos Securities plc (Nomad and Joint Broker) |
+44 (0) 20 7397 8900 | ||
| Michael Johnson/Russell Kerr (Sales) Stephen Keys/Camilla Hume (Corporate Finance) |
| ||
|
Singer Capital markets (Joint Broker) |
+44 (0) 20 7496 3000 | ||
| Jonathan Dighe (Sales) Shaun Dobson/Alaina Wong (Corporate Finance) |
| ||
|
|
| ||
About Venture Life (www.venture-life.com)
Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, Italy, The Netherlands and Sweden, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, the Balance Active range in the area of women's intimate healthcare, the Lift and Glucogel product ranges for hypoglycaemia, products for fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing. Its products are sold in over 90 countries worldwide.
The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and The Netherlands these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners.
Through its two Development & Manufacturing operations in Italy and Sweden, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.
The Company makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:
| 1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||
| a)
| Name
| Daniel Wells
| ||||
| 2
| Reason for the notification
| |||||
| a)
| Position/status
| Chief Financial Officer | ||||
| b)
| Initial notification /Amendment
| Initial notification | ||||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||
| a)
| Name
| Venture Life Group plc | ||||
| b)
| LEI
| 213800S8CZUPLAB2KC70 | ||||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||
| a)
| Description of the financial instrument, type of instrument
Identification code
| Ordinary Shares of 0.3p each in Venture Life Group plc
GB00BFPM8908 | ||||
| b)
| Nature of the transaction
| Grant of new options for ordinary shares | ||||
| c)
| Price(s) and volume(s)
|
| ||||
| d)
| Aggregated information
- Aggregated volume
- Price
| n/a
| ||||
| e)
| Date of the transaction
| 22nd February 2022 | ||||
| f)
| Place of the transaction
| n/a | ||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
